Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (101-110 of 199) with videos related to

Pageof 20
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2014
Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioningRan Reshef, Elizabeth O Hexner, Alison W Loren, et al.
Blood|September 27, 2019
CAR T cell viability release testing and clinical outcomes: is there a lower limit?Elise A Chong, Bruce L Levine, Stephan A Grupp, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2018
Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical TrialRan Reshef, Alex Ganetsky, Edward P Acosta, et al.
Transplantation and Cellular Therapy|May 21, 2023
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T CellsDaniel J Landsburg, Sunita D Nasta, Jakub Svoboda, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
The New England Journal of Medicine|December 12, 2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasStephen J Schuster, Jakub Svoboda, Elise A Chong, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Bone Marrow Transplantation|May 26, 2018
Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tractAlex Ganetsky, Noelle V Frey, Elizabeth O Hexner, et al.
Pageof 20

Showing results (101-110 of 199) with videos related to

Sort By:
Pageof 20
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2014
Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioningRan Reshef, Elizabeth O Hexner, Alison W Loren, et al.
Blood|September 27, 2019
CAR T cell viability release testing and clinical outcomes: is there a lower limit?Elise A Chong, Bruce L Levine, Stephan A Grupp, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2018
Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical TrialRan Reshef, Alex Ganetsky, Edward P Acosta, et al.
Transplantation and Cellular Therapy|May 21, 2023
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T CellsDaniel J Landsburg, Sunita D Nasta, Jakub Svoboda, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
The New England Journal of Medicine|December 12, 2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasStephen J Schuster, Jakub Svoboda, Elise A Chong, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Bone Marrow Transplantation|May 26, 2018
Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tractAlex Ganetsky, Noelle V Frey, Elizabeth O Hexner, et al.
Pageof 20